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Abstract
Genome-wide association studies (GWAS) have defined over 150 genomic regions unequivocally containing variation
predisposing to immune-mediated disease. Inferring disease biology from these observations, however, hinges on our ability
to discover the molecular processes being perturbed by these risk variants. It has previously been observed that different
genes harboring causal mutations for the same Mendelian disease often physically interact. We sought to evaluate the degree
to which this is true of genes within strongly associated loci in complex disease. Using sets of loci defined in rheumatoid
arthritis (RA) and Crohn’s disease (CD) GWAS, we build protein–protein interaction (PPI) networks for genes within associated
loci and find abundant physical interactions between protein products of associated genes. We apply multiple permutation
approaches to show that these networks are more densely connected than chance expectation. To confirm biological
relevance, we show that the components of the networks tend to be expressed in similar tissues relevant to the phenotypes in
question, suggesting the network indicates common underlying processes perturbed by risk loci. Furthermore, we show that
the RA and CD networks have predictive power by demonstrating that proteins in these networks, not encoded in the
confirmed list of disease associated loci, are significantly enriched for association to the phenotypes in question in extended
GWAS analysis. Finally, we test our method in 3 non-immune traits to assess its applicability to complex traits in general. We
find that genes in loci associated to height and lipid levels assemble into significantly connected networks but did not detect
excess connectivity among Type 2 Diabetes (T2D) loci beyondchance. Taken together, ourresults constituteevidence that, for
many of the complex diseases studied here, common genetic associations implicate regions encoding proteins that physically
interact in a preferential manner, in line with observations in Mendelian disease.
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Introduction
Common genetic variants in over 150 genomic loci have now
been unequivocally associated to immune-mediated diseases by
genome-wide association studies (GWAS) [1–18]. It is presumed
that these associations represent perturbations to a common but
limited set of underlying molecular processes that modulate risk
to disease. The next challenge – and the great promise of human
genetics – is the identification of these disease-causing pathways
so they may be targeted for diagnostics and therapeutic
intervention.
In identifying such processes, there are difficulties in both (i)
identifying the specific genes at (and how they are molecularly
impacted by) each association and (ii) inferring disease-causing
mechanisms from the set of identified genes. Linkage disequilib-
rium blocks containing disease-associated SNPs can be hundreds
of kilobases in size, and some contain tens of genes to consider.
Genes are often informally implicated in pathogenesis by their
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plausibility, or simply their being the only protein-coding gene
in the region. In reality, however, it is only a very small subset of
confirmed GWAS associations for which specific functional
variants have been proven experimentally.
More systematic approaches have been applied to connect
genes to a common process with the use of independent data, such
as Gene Set Enrichment Analysis (GSEA) and Gene Relationships
Across Implicated Loci (GRAIL) [1,19–21]. Both approaches
identify connections between genes based on descriptive categories
that outline the theorized underlying pathogenesis. However, these
concepts are often general, so that specific hypotheses and
molecular pathways can be difficult to define and are somewhat
limited to established knowledge bases.
Observations of interactions between the products of protein-
coding genes offer the most direct route to identifying pathogenic
processes. Ithasbeen shown ina numberofMendelian diseasesthat
genes causal of a particular phenotype tend to physically interact
[22–26]. This has been confirmed in the model organism C. elegans,
where RNAi knock-down of germline genes correlated highly with
their products interacting in yeast-two hybrid experiments [26]. A
classicexampleofahumanMendeliandisease thatrecapitulatesthis
model is Fanconi Anemia (FA), an autosomal recessive disorder
linkedto at least13loci, at least8 of whichfunctionina DNArepair
complex [22]. Protein-protein interaction (PPI) data has also been
used to formulate hypotheses about co-expressed genes as well as
cancer genes [27,28]. We note that previous attempts to use PPI
data to prioritize candidate genes in Mendelian disorders have been
successful as was the case with the published tool Prioritizer [29]. We
therefore set out to test such an approach in complex disease.
Investigators have rapidly populated databases of such protein-
protein interactions over the past decade. The reported interac-
tions in PPI databases stem from both small, directed investiga-
tions and high-throughput experiments, primarily yeast two-
hybrid screens and affinity purification followed by mass
spectrometry [30]. These data are inherently noisy: beyond
technical false positives and negatives, experiments in vitro may
report interactions that do not occur in vivo simply because the
proteins involved never overlap spatially or temporally. To
mitigate the noisiness of PPI databases, we extract networks from
‘‘InWeb’’, assembled in 2007 by Lage et al [24,31]. InWeb is a
database of 169,810 high-confidence pair-wise interactions
involving 12,793 proteins (human proteins and their orthologs).
Lage et al. define high-confidence interactions as those seen in
multiple independent experiments and reported more often in
lower-throughput experiments [24]. To further restrict the data to
biologically plausible interactions, we overlay mRNA expression
information to confirm co-expression of binding partners; this
correlates with co-localization, similar phenotype and participa-
tion in a protein complex [31,32].
Assessing the significance of networks built from PPI data is
challengingfortworeasons: first,overallconnectivityis a function of
the binding degree (number of connections in the database for a
given protein) of proteins within the network. Thus, the apparent
density of a network could simply be due to the lack of specificity
withwhichitsconstituentsbindinvitro.Second,certainprocessesare
more extensively studied, so more connections between proteins
involved in them may be reported (see Figure S1; immune proteins
are reported in more publications and have a higher mean binding
degree). This confounds our effort to assess connectivity of
associated loci if there is a bias in the data. From a genetic
standpoint, a common randomization method would involve
sampling SNPs from the genome matched for the appropriate
parameters (such as gene density and protein binding degree). This
method becomes highly limited if the disease loci contain genes that
are better studied than the randomly sampled SNPs.
Therefore, we apply a permutation method that is robust to
non-specific binding and differences in publication density. We
perform a within-degree node-label permutation that is carried out
as follows: a random network is built that has nearly the exact
same structure as the original InWeb network, only the node labels
(i.e. the protein names) are randomly re-assigned to nodes of equal
binding degree; this method assumes a null distribution of
connectivity that is entirely a function of the binding degree of
individual proteins. Random networks will have the same size,
number of edges and per-protein binding degree as InWeb; we
build 50,000 different random networks. With this method, we are
able to test the non-randomness of our network conditional on the
exact binding degree distribution of our disease proteins.
Others have used PPI data in complex disease to understand
epistatic loci or to build a network of interacting proteins from
associatedloci[33–35].Thenoveltyofourmethodliesnotinthe idea
that PPIdatacanbe used tohelpunderstandgenetic lociassociated to
disease, but rather in that we have developed a broadly-applicable
method to statistically evaluate the degree to which non-random PPI
networks emerge from loci associated to complex disease and to
leverage from this insight about causal proteins in large loci [33,34].
We show this to be the case in a number of diseases.
Here, we use this methodology to evaluate whether genes in loci
associated to five complex traits are significantly connected via
protein-protein interactions. We report an algorithm to build and
assess PPI networks using the InWeb database and find robust,
statistically significant networks underlying associations to RA,
CD, height and lipid levels, which we suggest as representative of
the underlying pathogenic molecular processes. We then perform
several detailed analyses on the RA and CD networks to confirm
that they contain true biological insight into disease. We use
independent mRNA expression data to show that the prioritized
associated proteins we propose as interacting are co-expressed in
relevant immune tissues, supporting a plausible biological setting
for our findings as well as the validity of the reported protein-
Author Summary
Genome-wide association studies have uncovered hun-
dreds of DNA changes associated with complex disease.
The ultimate promise of these studies is the understanding
of disease biology; this goal, however, is not easily
achieved because each disease has yielded numerous
associations, each one pointing to a region of the genome,
rather than a specific causal mutation. Presumably, the
causal variants affect components of common molecular
processes, and a first step in understanding the disease
biology perturbed in patients is to identify connections
among regions associated to disease. Since it has been
reported in numerous Mendelian diseases that protein
products of causal genes tend to physically bind each
other, we chose to approach this problem using known
protein–protein interactions to test whether any of the
products of genes in five complex trait-associated loci bind
each other. We applied several permutation methods and
find robustly significant connectivity within four of the
traits. In Crohn’s disease and rheumatoid arthritis, we are
able to show that these genes are co-expressed and that
other proteins emerging in the network are enriched for
association to disease. These findings suggest that, for the
complex traits studied here, associated loci contain
variants that affect common molecular processes, rather
than distinct mechanisms specific to each association.
Proteins in Disease Regions Physically Interact
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meta-analysis results, we show that these networks contain
components that show significant evidence of further genetic
associations: proteins interacting with multiple associated network
members and encoded elsewhere in the genome themselves carry
an excess of association to disease in the latest meta-analyses of
each of these diseases. Our method, available for download,
generates an experimentally tractable hypothesis of the molecular
underpinnings of pathogenesis.
Results
Network Construction and Evaluation Pipeline
We construct and evaluate networks of disease loci as outlined
in Figure 1. We first define associated proteins as gene products
encoded in genomic loci harboring variants associated to disease
(Figure 1A, 1B; see Materials and Methods for locus definition).
We construct networks of protein-protein interactions representing
proteins as nodes connected by an edge if there is in vitro evidence
of interaction (InWeb high-confidence interaction set). We build
direct networks, in which any two associated proteins can be
connected by exactly one edge, and indirect networks, where
associated proteins can be connected via common interactor proteins
(not encoded in associated loci) with which the associated proteins
each share an edge. We restrict direct and indirect interactions to
only those between proteins encoded in distinct associated loci.
We then calculate several metrics to evaluate network
properties. These metrics can be divided into two categories: an
edge metric and node metrics. The edge metric is the direct network
connectivity parameter defined as the number of edges in the direct
network. We interpret direct network connectivity as the frequency with
which different loci harbor proteins that directly bind each other,
regardless of how they assemble; direct network connectivity is therefore
our most straightforward metric. Node metrics include the
following: associated protein direct connectivity and associated protein
indirect connectivity which refer to the number of distinct loci an
Figure 1. Pictorial outline of methodology. A. Genes overlapping the wingspan of associated SNPs are defined, and these genes code for
associated proteins. B. Associated proteins are used to recover direct and indirect networks. Direct networks (left) are built from direct interactions
between associated proteins according to the InWeb database (colored proteins). Connections between proteins within the same locus are not
considered. Indirect networks (right) are built by allowing connections between associated proteins through a protein elsewhere in the genome
(grey). Various network parameters to quantify connectivity, defined in the text, are assigned. C. Random networks are built from a within-degree
node-label permutation method described in Text S1. An empirical distribution is constructed for each network parameter and used to evaluate the
significance of networks. D. Using the same permutation method to score individual proteins, a subset of proteins per locus is nominated as
candidates for harboring causal variants (red circles). Scores used to nominate candidates, described in Text S1, are Bonferroni corrected for the
number of possible candidates within each locus. E. Candidate genes from D (nominal p-values used) are tested for co-expression.
doi:10.1371/journal.pgen.1001273.g001
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respectively, and common interactor connectivity which refers to the
average number of proteins in distinct loci bound by common
interactors in indirect networks. We interpret all three node
metrics as descriptive of the type of network that was constructed:
a stream of connections (such as the network A-B-C-D-E) will
likely have low and insignificant node metrics despite a significant
edge metric, whereas a more tightly clustered network might be
enriched for both edge and node metrics. We assess the statistical
significance of the various connectivity parameters using a within-
degree node-label permutation strategy that controls for variation
in the degree to which certain proteins are studied or behave in
vitro (Figure 1C; see Text S1 for details on the permutation
strategy, evaluation of its ability to distinguish signal from noise
and a benchmark analysis of Fanconi Anemia). As we are
interested in the processes underlying disease, we also define the
gene encoding the top-scoring protein in each locus as most likely
to be causal for association (Figure 1D; see Text S1 for
prioritization strategy). We then use tissue expression data to test
whether our nominated candidate genes are enriched in the same
tissue(s) and therefore participate in a network that is biologically
feasible (Figure 1E; Text S1). With this approach, we aim to
construct plausible models of biological networks underlying
pathogenesis.
Our approach controls for biases in the data: using the high-
confidence interactions from InWeb addresses laboratory artifacts,
and node-label permutation accounts for ascertainment biases due
to differing levels of knowledge on biological processes for those
proteins present in InWeb (Figure S1). We show empirically that
priority scores given to proteins have no correlation with the
degree to which they are represented in the database (Figure S2).
A fundamental limitation of any functional data is that genes for
which data are missing will not be considered. This applies to
similar methods, including expression data that can be limited to
genes represented on specific arrays or ontology analyses that are
restricted to well characterized genes. Here, proteins that are
entirely absent from the filtered InWeb data are not considered in
our analysis (see Discussion). It is important to note that these
genes, listed in Table S1, cannot be ruled out as potentially
affected by causal variation since we have no power to make such
a conclusion. We note, however, that the loci we have considered
here (for the 5 complex traits) have the majority of their genes
present in the high-confidence InWeb database (Table S1, median
inclusion of 81.5%).
We also tested two additional permutation strategies on RA and
CD – one based on random sampling of SNPs from the genome
matched for proximal gene content and protein binding degree
and the other based on edge permutation – that generally
provided equivalent results (Figures S3 and S4); however SNP
permutation may not be robust in the presence of extremes of gene
density or protein binding degree at some loci, and edge
permutation does not preserve the network structure of InWeb
(Text S1). This analysis pipeline, which we call Disease Association
Protein-Protein Link Evaluator (DAPPLE), is available for
download at http://www.broadinstitute.org/,rossin/DAPPLE.
Gene Products Encoded in Associated Loci Interact
We first tested the method on the Mendelian disease Fanconi
Anemia (FA) as a proof of principle. We input 9 of the FA genes
and found 23 connections among them; compared to 50,000
random networks, the FA network is enriched for connectivity
(direct network connectivity p,,2610
25, Figure S5, Text S1). This
result is consistent with current understanding of how the FA genes
code for proteins that are part of the same DNA repair complex
[36].
We then set out to test our method on two autoimmune diseases
that are both complex traits. Recent GWA studies in autoimmune
and inflammatory diseases have been particularly successful at
determining loci encoding risk to disease, with over 100 loci
described to date [2–7,1]. We investigated rheumatoid arthritis
(RA) and Crohn’s disease (CD) and built networks from proteins
encoded in 25 and 27 gene-containing associated loci, respectively
[2,8]. As described above, we built direct and indirect networks for
each set of loci, evaluated the significance of the 4 network metrics
to assess the probability that such networks could arise by chance,
and we nominated candidate genes by assessing network
participation. We followed up our results by assessing tissue co-
expression as a test for the biological feasibility.
We were able to connect 20/27 loci for RA and 12/25 loci for
CD in direct networks, strongly suggesting functional connections
between proteins encoded in the associated regions. When
compared to 50,000 random networks, we found that the direct
network connectivity (the number of direct network edges) was
statistically significant (27 for each disease; PRA=3 610
24,
PCD=1.11610
23; Figure 2) as was the associated protein direct
connectivity (Figure S6A and S6B, PRA=0.02, PCD=0.00305). Thus
disease-associated loci encode directly interacting proteins beyond
chance expectation, suggesting that risk variants may act on suites
of proteins involved in the same process.
We were then able to connect all but one gene-containing
associated loci in each disease by expanding our networks to
include common interactors (26/27 in RA; 24/25 in CD). The
associated protein indirect connectivity was significantly enriched in both
diseases (Figure S6A and S6B p=1610
25 in RA, p=4.1610
24
for CD), as was the common interactor connectivity (Figure S6A and
S6B, p=7 610
25 for RA and p=1.1610
24 for CD).
In aggregate, these results suggest that the observations of
connectivity in Mendelian diseases are recapitulated in both RA
and CD and that common risk variants predisposing to these
diseases may impact sets of interacting proteins.
Given the significant connectivity of common interactors in the
indirect networks for RA and CD, we speculated that common
interactors might themselves be affected by previously undescribed
risk variation. To test this, we consulted association data for each
disease in the available data from meta-analyses, which for RA was
in a newly completed meta-analysis and for CD was the same
study that yielded the 30 loci [2,37]. We assigned each
recombination hotspot-bounded linkage-disequilibrium (LD) block
in the genome an association score that represents the maximum
score in that block corrected for the number independent SNPs
therein. Genes were assigned association scores based on the
blocks they overlap; this score distribution can then be compared
to the scores of all gene-containing blocks in the genome (for both
diseases, we removed the MHC from this analysis due to LD
properties). Using this method, we found that common interactors
expressed in the same tissues as associated proteins in our networks
(see below) were encoded in regions with evidence of association
significantly in excess to what is expected in gene-containing
regions. In RA, the distribution of common interactor scores was
skewed toward higher association (one-tailed rank sum
p=1.7610
25) and in CD, we saw similar enrichment
(p=6.5610
24). See Text S1 for details of analysis. This observed
skew suggests that the common interactors themselves may harbor
risk variants; we therefore considered the regions they overlap as
candidates for replication (see ‘‘Crohn’s Network Predicts New
Loci’’ section).
Proteins in Disease Regions Physically Interact
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To test whether the observed significant connectivity seen in RA
and CD was present in non-immune complex traits, we tested our
method on three traits: human height, blood lipid concentration
(both LDL and HDL) and Type 2 Diabetes (T2D). We used 37
replicated gene-containing loci associated with human height, 18
with blood lipid levels and 36 with T2D [9–17]. The loci
associated to height and lipids each contain proteins that assemble
into significantly connected direct networks (Figure S6C and S6D,
direct network connectivity p=1 610
24 and p=1.9610
24 for each
disease, respectively; see Text S1 for significance of other 3
parameters). In the height network, 19/42 loci participated in the
direct network and 34/42 participate in the indirect networks, but
only the direct network connectivity and the common interactor connectivity
were significantly greater than chance. In the lipids network, 11/
19 participated in the direct network and 16/19 in the indirect; all
node metrics except the common interactor connectivity were signifi-
cantly enriched. 9/37 T2D loci participated in the direct network
and 34/37 in the indirect network; however, 3/4 metrics were not
greater than chance expectation and only one was slightly
enriched (Figure S6E, network connectivity p=0.44960; see Text S1
for significance of other 3 parameters).
We therefore conclude that the PPI connectivity seen in two
autoimmune diseases can be generalized to other complex trait
loci (height- and lipid-associated regions), though we could not
confirm the significance of the T2D network.
Our results suggest that functionally connected proteins reside
in regions of the genome associated to disease risk. Permutation
analysis revealed that these connections are in excess compared to
what is expected given the binding profiles of associated proteins.
For RA and CD, other proteins interacting with the associated
proteins also show evidence of association beyond chance
expectation. Cumulatively, these findings suggest that risk to the
complex disease/traits studied here is spread over functional
groups of proteins, directly analogous to observations in
Mendelian traits.
Prioritizing Proteins in Associated Loci Reveals Likely
Pathogenic Tissues
An obstacle to interpreting GWA results stems from the
difficulty in identifying the genes within associated regions
influenced by risk variants. Candidate genes are often selected
based on proximity to most associated markers and miscellaneous
forms of previous knowledge. We therefore asked whether our
observations could lead us to a principled, data-driven approach to
selecting candidate genes by assessing their role in our networks.
As shown in Figure 1 and described in detail in the Text S1, we
used an iterative optimization method to assign priority scores to
associated genes based on the network participation of their
encoded proteins. We nominate genes that achieve the best score
within their locus as the candidates for influencing disease risk. We
describe the results in detail here for RA and CD; see Table S2 for
scores assigned to RA, CD, blood lipid level and height genes.
We were able to nominate candidate genes in 12/21 RA loci
encoding multiple genes (Table S2; Text S1). Examples of
candidate genes in RA were IL2RA, CD40, CD28, PTPN22,
CTLA4 and TRAF1. We accomplished the same task in CD,
nominating candidate genes in 10/18 multi-genic loci. Candidates
included JAK2, STAT3, IL23R/IL12RB2, PTPN2, MST1R and
AIRE. For both diseases, genes in single-gene loci are also scored,
though they are automatically considered the candidate gene (but
not necessarily part of the underlying mechanism). It is important
to note that we do not expect high-scoring proteins in every locus;
we only expect high scores for those proteins that may participate
in the common process(es) detected via enrichment in connections.
RA and CD, like most complex diseases, most likely have many
underlying processes, not all of which are captured here.
The core networks involving only these candidate genes
represent our mechanistic predictions of pathways underlying
pathogenesis in RA and CD. From a statistical standpoint the final
networks built from candidate proteins account for the excess
connectivity that we initially observed: the significance remains if
we restrict multi-genic loci to just these genes (Figure S7A–S7D,
Figure 2. RA and CD direct networks are significantly interconnected. The direct network connectivity, the number of edges in the direct
network, was enumerated for the disease networks and 50,000 random networks. A histogram was plotted to represent random expectation, and the
disease network is shown by an arrow for (A) RA and (B) CD. See Figure S6 for remaining parameters and for parameters of height, lipids and T2D.
doi:10.1371/journal.pgen.1001273.g002
Proteins in Disease Regions Physically Interact
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25 for RA and CD), while
networks built from the remaining non-prioritized genes are less
significant (Figure S8, direct network connectivity p=0.0368 and
p=0.993, for RA and CD respectively). The remaining signifi-
cance in RA is most likely a sign of additional important proteins
that did not make the cutoff. From a biological standpoint, our
candidates agree with experimental findings in the few cases where
such evidence exists [38–45]. We therefore show that the
connectivity between associated loci in RA and CD is primarily
driven by a small subset of associated proteins encoded in those
regions; this observation suggests that the interacting proteins –
and the biological pathways they represent – may be the targets of
risk variation.
To test the biological plausibility of our nominated core
networks, we asked whether the candidate genes are co-enriched
in subsets of particularly relevant tissues in a reference microarray
dataset consisting of 14,184 transcripts measured in 55 immune, 8
gastro-intestinal, 27 neurological and 36 miscellaneous other
tissues (126 total) [46]. These publicly available data are curated:
expression intensities were converted to enrichment scores to
reflect the enrichment of a gene in a tissue given its expression in
all tissues. For each tissue, we compared the expression
enrichment of RA and CD candidate genes to the rest of the
genes in the genome using a one-tailed rank-sum test, resulting in a
p-value for each tissue. A significant difference for a given tissue
indicated that the genes in question were enriched for expression
in that tissue compared to all genes in the genome. We also
performed the same analysis for the remaining non-prioritized
genes in associated regions to test whether the network
prioritization method identified genes that were enriched in tissues
distinct from non-prioritized genes. For discussion purposes, we
defined ‘‘top’’ tissues as tissues achieving p,0.1 (Figure 3 depicts
the entire distribution of p-values). This analysis led to 3 main
conclusions. First, we found that for each disease, enrichment only
occurred in immunologically relevant tissues (Figure 3; strikingly,
immune tissues are nearly all ranked higher than other tissues).
Second, we found that this was not the case to such an extent for
non-prioritized genes (Figure 3, black points). Third, we found that
the non-prioritized genes had fewer tissues where we could detect
enrichment (Figure 3, RA and CD candidate gene tissue scores are
more significant than tissue scores of non-prioritized genes). We
formally tested this by comparing the p-value distributions for
candidate genes and non-prioritized genes using a one-tailed rank-
sum test (p=2.85610
27 for RA; p=2.55610
24 for CD). Of the
11 top tissues for CD candidate genes, 7 are subgroups of T-cell
lymphocytes; the analogous list for RA (21 tissues) contains a mix
of immune tissues, again dominated by T-cell subgroups (Table 1).
The top tissue compartment for both diseases is defined as CD4+
T-cells.
Crohn’s Network Predicts New Loci
We hypothesized that a subset of proteins connected to the core
CD network (Figure 4B, the network built from prioritized genes
in CD loci) might be near true causal variation. Having observed
significant enrichment for association in the common interactors,
we then chose a more conservative approach to propose candidate
genes. We selected all proteins that connect directly to the core
CD network only (21 genes) and filtered them on expression in the
relevant tissues (Table 1). While this manuscript was being
prepared, a larger meta-analysis was completed and recently
published that reports 39 new loci associated to CD (295
overlapping genes) [47]. Of the 293 genes proposed by our
method (small circles, Figure 4B), 10 were in newly associated
regions (small red circles). This represents a statistically significant
enrichment compared to chance expectation based on random
draws from all 21,718 genes (p=0.001) as well as random draws
from genes expressed in at least one of the CD-relevant tissues
(p=0.01).
Figure 3. Candidate RA and CD genes are preferentially
expressed in immune tissues. We obtained tissue expression data
for 126 different cell types from a publicly available database, which
was grouped into immune, gastrointestinal (GI), neuronal and ‘other’
[46]. For each tissue, we compared the expression of RA (A) and CD (B)
candidate genes to the rest of the genes in the genome using a one-
tailed rank-sum test, resulting in a p-value for each tissue (-log(p) is
plotted on the y-axis). A significant difference for a given tissue
indicated that the candidate genes were enriched for expression in that
tissue compared to all genes in the genome. To test whether our
network prioritization identified genes that were co-enriched in specific
tissues beyond what was expected from all genes in associated regions,
we calculated the same p-values for the rest of the genes in RA and CD
associated loci (i.e., the genes that weren’t prioritized via our network
permutations). In this figure, we plot the tissue enrichment scores for
each tissue for the candidate genes (purple) and the non-prioritized
genes in the remaining regions of association (black). We indicate the
category of tissue on the bottom: immune (red), GI (yellow), neuronal
(green) and other (blue). We ordered the tissues by decreasing
enrichment score of the candidate genes.
doi:10.1371/journal.pgen.1001273.g003
Proteins in Disease Regions Physically Interact
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analysis discovered 6 new loci (18 new genes) [37]. Of the 610
genes proposed, 1 was among the 18 new genes (Figure 4A, small
red circle). This does not represent a statistically significant
enrichment.
Candidate Gene Networks Suggest Underlying Biology
The networks (Figure 4) suggest pathogenic mechanisms in
agreement with current thinking on disease etiology and propose
novel roles for candidate proteins in these pathways. The RA
network (Figure 4A) appears to represent signaling cascades involved
in the inhibition or stimulation of the NF-kB complex, a factor that
activates transcription of genes encoding cytokines, antibodies, co-
stimulatory molecules and surface receptors [43]. STAT4 encodes a
transcription factor that is activated upon engagement of cytokines,
such as IL12 and interferon type I, with their receptors [43]. We
show that not only does STAT4 show enrichment for connectivity, it
is connected indirectly to a number of associated genes encoding
surface receptor subunits that also achieve high network scores, such
as IL12RB, IL2RA and PTPRC. TNFAIP3 (known as A20 in mice)
is a cytoplasmic zinc finger protein that inhibits NF-kB activity, and
knockout mice develop widespread and ultimately lethal inflamma-
tion, making it a plausible player in RA pathogenesis [48]. Also in
the NF-kB pathway is associated protein CD40, which scores highly
in our networks and binds TRAF6 and TRAF1 directly. CD40 is
normally found on B cells but has also been shown to act as a co-
stimulatory molecule on T cells to augment CD28 response and
activate NF-kB [49].
PTPN22, a gene with strong genetic support for harboring risk
variants (including the strongly associated R620W coding polymor-
phism), has been shown to act as a negative regulator of TCR but
has not yet been definitively linked to a pathogenic mechanism
[43,50]. Here, we place it in context of other highly associated
proteins and suggest that it is part of a common mechanism.
Finally, the RA network places a number of other proteins that
have not yet been formally studied in the context of the proposed
network underlying RA; these include CD2 and CD48, as well as
FCG2RA and PRKCQ, genes suspected of being causal but not
formally placed in a mechanism with other associations.
In CD the core of the candidate network (IL12B/IL23R/
JAK2/STAT3; Figure 4B) corresponds to the interleukin-23
(IL23) signaling pathway. IL12B encodes p40, a component of
the heterodimeric IL23. The IL23R gene encodes one half of the
also heterodimeric IL23 receptor. This receptor is a cell surface
complex found on a variety of immune cells; on activation, it
induces Janus Kinase 2 (Jak2) autophosphorylation, which in turn
leads to the translocation of STAT3 to the nucleus to activate
transcription of various pro-inflammatory cytokines [40]. IL23
signaling is necessary for the activation and maintenance of a
subset of CD4
+ T cells acting as ‘inflammatory effectors’; these
interleukin-17 responsive T-cells (Th17) have been implicated in
autoimmune inflammation in CD and experimental models of
other autoimmune diseases [40]. We note that IL23 belongs to the
interleukin 12 family of cytokines and both ligand and receptor
share subunits with the canonical IL12-mediated signaling
pathway, which induces activation of regulatory T cells (Treg).
Table 1. RA and CD candidate genes are preferentially expressed in immune tissues.
Rheumatoid arthritis Crohn’s disease
Tissue p-value Tissue p-value
TonsilsCD4posTcells 1.21E-06 Tcellseffectormemory 0.010879534
Th1 3.60E-06 TcellsBAFFpos 0.021533643
TcellsCD57pos 5.74E-06 Treg 0.040222981
Treg 2.42E-05 Tcellscentralmemory 0.047167636
Lymphnode 4.58E-05 ThymicSPCD8posTcells 0.052512983
Th2 5.42E-05 PeripheralnaiveCD4posTcells 0.062360126
TcellsBAFFpos 0.00012286 ThymicSPCD4posTcells 0.063736236
PeripheralCD8posTcells 0.000416196 MacrophageLPS4h 0.067420383
Tcellscentralmemory 0.000547856 MyeloidCD33pos 0.082208219
Tcellseffectormemory 0.000896003 PeripheralCD8posTcells 0.083132825
Tonsils 0.003590718 DC 0.090095533
ThymicSPCD8posTcells 0.005276588
ThymicSPCD4posTcells 0.010418466
PeripheralnaiveCD4posTcells 0.011665294
NKCD56pos 0.017592624
Tcellsgammadelta 0.018660953
MacrophageLPS4h 0.029525421
DC 0.046402891
Spleen 0.048696618
DCLPS48h 0.063014104
ThymicCD4posCD8posCD3pos 0.091299315
Expression data was downloaded from a publically available dataset [46]. The data had been previously converted into enrichment scores (see Materials and Methods).
The enrichment scores of candidate genes in RA and CD were compared to the rest of the genome by a one-tailed rank-sum test. The tissues that received a p-value of
,0.1 are shown. Of note, all tissues in this category for both RA and CD are immune, as shown in Figure 3.
doi:10.1371/journal.pgen.1001273.t001
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PLoS Genetics | www.plosgenetics.org 7 January 2011 | Volume 7 | Issue 1 | e1001273Our CD network suggests that other proteins participate in this
pathway, including the tyrosine phosphatases encoded by PTPN2,
a gene also associated to other autoimmune diseases [51]. Other
proteins that are indirectly connected to this pathway include
IRF1, which we score highly and that has separately been reported
to activate transcription of IL12RB1 [52]. Furthermore, the
common interactors that we prioritize for replication of association
given their involvement in the CD network – including JAK1,
STAT4, TYK2 and IL2RA – fall into the IL12 and IL23 signaling
pathway (TYK2 and IL2RA were of the genes recently found to be
in regions of association).
The CD network also generates new hypotheses about
potentially important genes. We prioritize AIRE, an associated
protein involved in T-cell development, which has not been
extensively studied in the context of Crohn’s but could plausibly
lead to autoimmunity. ZNF365, a gene that achieves a high
permutation score, has been assumed to be the causal gene
because it is the only gene to reside in the wingspan of its locus;
however, it has not been studied as part of the core network
described here (IL23R/JAK2/STAT3 pathway). Finally, CSF2,
IKZF3 and GRB7 are in the same large locus (17 genes) but achieve
significant permutation scores; these genes have been less well
studied in the context of CD.
Discussion
WehaveshownthatproteinsencodedinregionsassociatedtoRA,
CD, height and lipids interact and that the networks they form are
significantly connected when compared to random networks. In CD
and RA, the genes encoding prioritized proteins are preferentially
expressed in immune tissues relevant to the pathogenesis of both
diseases, while the rest of the genes in associated loci show less tissue
preference. Furthermore, we can connect other associated proteins
to these networks via common interactors, which appear to be
encoded in genomic regions harboring further risk variants. Newly
availabledatainCDallowedustoconfirmthatgenespredictedtobe
near causal variation are indeed in regions now known to be
associated to CD. We note that the conclusion of connectivity could
not be extended to T2D, and we hypothesize that the lack of
connectivity may be due to disparate underlying mechanisms that
have yet to be well captured genetically. Though our aim was to
build and analyze networks that emerge from replicated regions of
association, we feel that a promising future direction may be to look
more broadly for networks enriched in weaker signals of association.
Evidence that this type of analysis may be helpful is that we pointed
to a set of weaker CD association signals that were found to be true
positives in a larger study.
Our results have several implications for the interpretation of
genome-wide association studies: first, our ability to connect the
majority of associated loci in a limited number of molecular
networks suggests that these represent processes underlying
pathogenesis. Second, these networks are unbiased, in the sense
that they do not rely on previous classifications of gene function or
pathway lists; rather, we assemble our networks from low-level
functional genomics data and allow network structure, if any, to
emerge. Third, our approach is general; we have demonstrated it
using interactions between protein products, but any relationship
between genes or other genomic features (non-coding RNAs,
enhancer elements, conserved regions etc.) may be used in the
same fashion. Even more powerful, approaches combining such
orthogonal data types will be rewarding. The limitation to using
PPI data from a curated database such as InWeb is that proteins
for which no high-confidence interactions exist will be left out of
the analysis. As such, our analysis is limited to proteins present in
the database. Additionally, while we controlled for the biases we
observed, other undetected biases still may exist.
Figure 4. Final disease networks. Resultant networks built from candidate genes are depicted for RA and CD (A and B, respectively). Using only
the candidate genes, we plotted the direct network as well as any other proteins connected to the direct network after filtering them on expression
in any one of the tissues found to be specific to the core network. 610 such proteins connect to the RA network and 293 such proteins connect to the
CD network. Large circles represent disease proteins, and small circles represent the connected proteins. Small red circles indicate proteins connected
to the core network that were newly identified associated regions (10 proteins in CD and 1 protein in RA). The large circles are colored by locus.
doi:10.1371/journal.pgen.1001273.g004
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distinguish between proteins that are close in the genome and
functionally very similar. In RA, the rs12746613 locus has 3 genes
in the PPI database – FCG2RA, FCGR3A and HSP70B. FCG2RA
achieved a nominal p-value of 0.00703, whereas FCGR3A
achieved p=0.38296. Similarly, in the large rs3197999 locus in
CD, the method gave MST1R a p-value of 0.0066 whereas MST1,
the ligand of MST1R, achieved a p-value of 1. In these cases, the
method is able to distinguish between functionally similar genes.
There are times when it is unable to distinguish between
functionally similar genes, however, such as the IL21/IL2 locus
in RA, the STAT1/STAT4 locus in RA and the STAT3/STAT5A/
STAT5B locus in CD.
We note in passing that the candidate genes we nominate are
on average the closest to the most associated SNP in each locus,
even though proximity within the LD region was not considered
in the PPI analysis (p=0.005, Figure S9). This supports the
theory that the majority of causal variation will be close to the
association signal rather than anywhere in the region of LD. We
also observed overlap between genes prioritized by this method
and GRAIL, a text-mining approach that uses orthogonal data
(Table S2) [19]. We depict this information, as well as overlap
between prioritized genes and the presence of non-synonymous
SNPs, in Figure S10.
In this paper, we have studied 5 complex phenotypes, 4 of
which show evidence of abundant PPI connections across loci.
Our results therefore allow us to speculate that other complex
diseases may behave in the same way and that genetic risk may be
spread over the molecular processes that influence disease, rather
than a single, catastrophic mutation as in Mendelian inheritance.
In order to determine whether what we find here is expandable to
complex disease in general, however, we would need to apply our
method to the many more diseases and traits to which regions of
the genome have been associated. Nonetheless, for the networks
that emerge here, our approach identifies sets of proteins plausibly
involved in pathogenesis, and the next step will be to identify what
the molecular and phenotypic consequences of perturbing such
processes are and how they relate to overall disease etiology.
Materials and Methods
InWeb Database
We used a probabilistic database of reported protein-protein
interactions described in 2007 by Lage et al [24,31]. This database
contains 428,430 reported interactions, 169,810 of which are
deemed high-confidence, non-self interactions across 12,793
proteins. High-confidence is defined by a rigorously tested signal
to noise threshold as determined by comparison to well-established
interactions [24]. Briefly, InWeb combines reported protein
interactions from MINT, BIND, IntAct, KEGG annotated
protein-protein interactions (PPrel), KEGG Enzymes involved in
neighboring steps (ECrel), Reactome and others as described
elsewhere in detail [53–61]. All human interactions were pooled
and interactions in orthologous protein pairs passing a strict
threshold for orthology were included. Each interaction was
assigned a probabilistic score based on the neighborhood of the
interaction, the scale of the experiment in which the interaction
was reported and the number of different publications in which the
interaction had been sited. The data we used is available at www.
broadinstitute.org/,rossin/PPI/ppi.html.
Disease Loci
30 CD SNPs were derived from the first CD meta analysis of
which 25 contain genes [2]. 28 RA SNPs were derived from the
most recent RA review of which 27 contain genes [8]. 42 Height
SNPs were derived from a number of analyses of which 38 contain
genes [10,13,16]. 19 blood lipid level SNPs were derived from a
number of analyses of which all 19 contain genes [11,15]. Finally,
42 T2D SNPs were derived from a number of analyses of which 37
contain genes [9,12,14,17].
Translating SNPs to Genes
Hotspot and linkage disequilibrium (LD) information were
downloaded from www.hapmap.org for CEU hg17 and hg18 to
match the version in which associations were reported [62]. We
defined the wingspan of a SNP as the region containing SNPs with
r
2.0.5 to the associated SNP; this region is then extended to the
nearest recombination hotspot. We downloaded the Ensembl
human gene list from UCSC Genome Browser and collapsed
isoforms into single genes [63]. We converted gene IDs from
Ensemble to InWeb IDs. A gene’s residence in a locus is defined
by whether 110 kb upstream and 40 kb downstream (to include
regulatory DNA) of the coding region of the gene’s largest isoform
overlaps the SNP wingspan [64].
Statistical Analysis
All analyses, including building networks and evaluating
significance, were carried out in R, Perl and Python and are
available at www.broadinstitute.org/,rossin/PPI/ppi.html. De-
tails on the algorithms are available in the Text S1 file.
Supporting Information
Figure S1 Immune proteins are more likely to be in publications
involving reported protein-protein interactions. For each protein,
we enumerated the number of unique publications in which it is
reported. We then categorized proteins as ‘‘immune’’ or ‘‘non-
immune’’ based on the same expression data used in Figure 3.
Genes in the top 2% of expression for at least 2 of the 55 immune
tissues were deemed immune genes; their proteins were then
deemed immune-proteins. The distribution of publications for
immune proteins is significantly different than the background
distribution (Kolmogorov-Smirnov p-value ,2E-16).
Found at: doi:10.1371/journal.pgen.1001273.s001 (0.13 MB TIF)
Figure S2 Correlation between prioritization p-value and
binding degree. We show that there is no correlation between
prioritization p-values given to genes and their representation in
the database. We show this in randomized networks (A) and in the
disease networks (B).
Found at: doi:10.1371/journal.pgen.1001273.s002 (0.31 MB TIF)
Figure S3 RA and CD networks are significantly connected
when tested by SNP matching. As a test for robust enrichment in
connectivity, we built 1,000 networks from SNPs matched for gene
density throughout the genome for both RA and CD. These
networks were then filtered for SNPs whose associated genes have
a comparable binding degree distribution to those in RA and CD
(847 remain in RA, 353 remain in CD, see Text S1). We show the
expected random distribution in relation to the disease network for
each of the 4 parameters (direct network connectivity, associated
protein direct connectivity, associated protein indirect connectiv-
ity, common interactor connectivity) for RA (A) and CD (B).
Permuted networks were generated as described in Text S1.
Results found by node-label permutation were similar, though less
so for RA. From left to right and top to bottom for RA, p=0.005,
=0.013, =0.07, and =0.06. From left to right and top to bottom
for CD, p= ,0.001, =0.003, ,0.001, and =0.033.
Found at: doi:10.1371/journal.pgen.1001273.s003 (0.69 MB PDF)
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PLoS Genetics | www.plosgenetics.org 9 January 2011 | Volume 7 | Issue 1 | e1001273Figure S4 RA and CD networks are significantly connected
when tested by edge shuffling. As a test for robust enrichment in
connectivity, we built 1,000 networks using an edge shuffling
method (see Text S1 for details). We show the expected random
distribution in relation to the disease network for each of the 4
parameters (direct network connectivity, associated protein direct
connectivity, associated protein indirect connectivity, common
interactor connectivity) for RA (A) and CD (B). Permuted
networks were generated as described in Text S1. Results found
by node-label permutation were similar. From left to right and top
to bottom for RA, p,0.001, =0.013,,.001, and ,0.001. From
left to right and top to bottom for CD, p= ,0.001, ,0.001,
,0.001, and =0.001.
Found at: doi:10.1371/journal.pgen.1001273.s004 (0.70 MB PDF)
Figure S5 Fanconia Anemia network. As a benchmark analysis,
we tested the method on Fanconia Anemia, a Mendelian disorder
known to be caused by genes coding for interacting proteins. 9 of
the 13 FA genes were in the InWeb database. We found that the
direct network connectivity was 23, which is many more than
expected by chance (p,,2E-5). The associated protein direct
connectivity, associated protein indirect connectivity and common
interactor connectivity were all significantly enriched (p,2E-5,
p=0.004, p=0.009, respectively). These results agree with the
current understanding of FA pathogenesis. FA Network is shown.
Found at: doi:10.1371/journal.pgen.1001273.s005 (0.12 MB PDF)
Figure S6 Network parameters for RA, CD, Height, Lipids, and
T2D. We show the expected random distribution in relation to the
disease network (arrow) for each of the 4 parameters (direct
network connectivity, associated protein direct connectivity,
associated protein indirect connectivity, common interactor
connectivity) for RA (A), CD (B), Height (C), Lipids (D), and
T2D(E). Permuted networks were generated as described in Text
S1. Connectivity parameter scores are as follows. RA: 0.00031,
0.02000, 2.9734E-5, 6.9380E-5. CD: 0.00121, 0.00336, 0.00023,
0.00014. Height: 1e-04, 0.8446, 0.192, ,2E-5. Lipids: 0.00018,
0.01810, 0.00092, 0.13537. T2D: 0.41698, 0.23713, 0.03202,
0.23713.
Found at: doi:10.1371/journal.pgen.1001273.s006 (2.82 MB PDF)
Figure S7 RA and CD networks built from candidate genes are
significantly connected. Using the permutation method, we
nominated candidate genes as those that are more highly
connected to the network than chance expectation. If such a
high-scoring protein is found, the remaining proteins in the locus
scoring p.0.05 are removed. The remaining network is
significantly enriched for connectivity. We show the null
distribution in relation to the disease network for each of the 4
parameters (direct network connectivity, associated protein direct
connectivity, associated protein indirect connectivity, common
interactor connectivity) for RA (A) and CD (B). From left to right
and top to bottom for RA, p,2E-5, =0.017, ,2E-5 and ,2E-5.
From left to right and top to bottom for CD, p,2E-5, =0.008,
,2E-5 and ,2E-5.
Found at: doi:10.1371/journal.pgen.1001273.s007 (0.70 MB PDF)
Figure S8 The remaining non-candidate proteins are not
enriched for connectivity in RA and CD. Those proteins that
are filtered out during the candidate gene process are not enriched
for connectivity. We show the expected random distribution in
relation to the disease network for each of the 4 parameters (direct
network connectivity, associated protein direct connectivity,
associated protein indirect connectivity, common interactor
connectivity) for RA (A) and CD (B). From left to right and top
to bottom for RA, p=0.0368, 0.2424, 0.7274 and 0.1748. From
left to right and top to bottom for CD, p=0.993, 0.999, 0.6558
and 0.7468.
Found at: doi:10.1371/journal.pgen.1001273.s008 (0.72 MB PDF)
Figure S9 Candidate genes are likely to be near to the associated
SNP. Candidate genes within multigenic loci were prioritized as
described. We defined the distance from a gene to the SNP that
tags it as the shortest of two distances: the distance from its start
codon to the SNP and its stop codon to the SNP. Genes within a
SNP’s wingspan are then given ranks as to how close they are to
the SNP (closest gene, 2nd closest gene, and so on). These
distances were collected for RA and CD and the distribution is
shown (salmon bars). We compared this distribution to the
distribution of 100 simulated distances as defined by random
assignment of candidate genes in associated loci (black hatched
bars). The distributions are significantly different (one-tailed
Kolmogorov-Smirnov test p=0.008).
Found at: doi:10.1371/journal.pgen.1001273.s009 (0.08 MB TIF)
Figure S10 Overlap of prioritized genes across methods. For
each SNP, we compared the prioritized genes through PPI
networks, through GRAIL and through presence of non-
synonymous SNPs. We show the overlap for all SNPs, where
two methods agree if at least one prioritized gene in the region is
the same.
Found at: doi:10.1371/journal.pgen.1001273.s010 (0.02 MB PDF)
Table S1 Enumerating genes included and missing from the
analysis. For each disease, each locus (column 2) is annotated with
the number of genes in the locus according to the Ensembl gene
list downloaded from the UCSC Genome Browser (column 3 and
6) and the number of genes in the locus for which InWeb high-
confidence binding data is available (column 4 and 7). The percent
of genes included in the analysis out of the total possible genes was
calculated (column 5). The median gene inclusion is 81.5%.
*Genes in the Ensembl gene list that are not protein-coding or
proven to be protein-coding (rna genes, pseudogenes, theoretical
proteins) are not included in the ‘‘All Genes’’ list.
Found at: doi:10.1371/journal.pgen.1001273.s011 (0.05 MB
XLS)
Table S2 CD and RA candidate genes proposed through
permutation. This file provides the candidate gene scores for all
CD and RA genes involved in the networks (A), a comparison of
prioritized genes to those of GRAIL and genes with coding SNPs
for Crohn’s disease (B), and a full comparison of GRAIL p-values
for all 4 significantly connected traits (C).
Found at: doi:10.1371/journal.pgen.1001273.s012 (0.13 MB
XLS)
Text S1 Supplementary Methods.
Found at: doi:10.1371/journal.pgen.1001273.s013 (0.06 MB
DOC)
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